01—Abstract
Summary
Summary of the 10-K filed February 23, 2011. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported fiscal 2010 net sales of $1,133.4 milliona, down 3.3% from $1,171.6 million in 2009, and a net loss attributable to common shareowners of $336.7 million, compared with net income of $114.4 million in 2009.
The loss was driven primarily by a $305.0 millionb goodwill impairment in the Preclinical Services (PCS) segment, $91.4 million of asset impairments (including $64.6 million for PCS-Massachusetts and $17.2 million for PCS-China), and a $30.0 million termination fee paid to WuXi PharmaTech in connection with the terminated acquisition. Operating loss was $298.5 million compared with operating income of $169.6 million a year earlier. Net sales in the Research Models and Services (RMS) segment rose 1.1% to $667.0 million, while PCS sales fell 8.8% to $466.4 million, and PCS operating results swung to a loss of $379.7 million.
Management described a challenging market in which large pharmaceutical customers cut R&D spending, consolidated, and delayed decisions, creating excess preclinical capacity and pricing pressure. The company launched four initiatives in December 2010: improving operating margin, improving free cash flow, disciplined investment in growth businesses (GEMS, Discovery Services, In Vitro and Biopharmaceutical Services), and returning value to shareholders. It authorized a $500.0 million stock repurchase program, raised to $750.0 millionc, and executed a $300.0 million accelerated stock repurchase that settled on February 11, 2011, with $397.1 million remaining on the authorization.
The company also announced it is pursuing strategic alternatives for its U.S. Phase I clinic in Tacoma, Washington, which is now presented as discontinued operations, and for its China preclinical facility. Liquidity became more constrained: total debt and capital lease obligations rose to $700.9 milliond at year-end from $492.8 million, and shareowners' equity fell to $687.4 million from $1,375.2 million.
Cash and cash equivalents were $179.2 million, and net cash from operating activities was $168.2 million, down from $215.6 million. The company stated it expects 2011 capital expenditures of approximately $50.0 million.
02—Key points
Key Highlights
- Net sales of $1,133.4 million in 2010, down 3.3% from $1,171.6 million in 2009.
- Operating loss of $298.5 million, versus operating income of $169.6 million in 2009, driven mainly by impairments and a termination fee.
- Goodwill impairment of $305.0 million in the PCS segment, plus asset impairments of $91.4 million in total.
- A $30.0 million termination fee paid to WuXi PharmaTech to terminate a previously announced acquisition agreement.
- Diluted loss per share from continuing operations of $5.25, compared with diluted earnings of $1.72 in 2009.
- Total debt and capital lease obligations increased to $700.9 million from $492.8 million, while shareowners' equity fell to $687.4 million.
- A $750.0 million stock repurchase authorization, with a $300.0 million accelerated repurchase settled in February 2011 and $397.1 million remaining.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2010, Charles River Laboratories International lost $0.30.
- Revenue$1.13B100.0%
- Cost of revenue−$253.0M22.3%
- Gross profit$880.5M77.7%
- Operating costs−$1.18B104.0%
- Operating income−$298.5M26.3%
- Interest, other & tax−$38.2M3.4%
- Net income−$336.7M29.7%
04—Financials
Financial Highlights
Figures from 10-KFY2010filed February 23, 2011Financial Statements
FY2010 against FY2009
| Line item | FY2010FY2009 | Change |
|---|---|---|
| Revenue | $1.13B$1.17B | −3.3% |
| Cost of Revenue | $252.96M$255.68M | −1.1% |
| Gross Profit | $880.45M$915.96M | −3.9% |
| SG&A Expenses | $232.49M$227.66M | +2.1% |
| Operating Income | -$298.51M$169.61M | −276.0% |
| Interest Expense | $35.28M$21.68M | +62.7% |
| Net Income | -$336.67M$114.44M | −394.2% |
| EPS (Basic) | $-5.38$1.75 | −407.4% |
| EPS (Diluted) | $-5.38$1.74 | −409.2% |
| Shares Outstanding (Basic) | 62.56M65.37M | −4.3% |
| Shares Outstanding (Diluted) | 62.56M65.64M | −4.7% |
05—Questions
Frequently Asked Questions
Why did Charles River report a net loss in 2010 after a profitable 2009?
The net loss attributable to common shareowners of $336.7 million was primarily due to a $305.0 million goodwill impairment in the PCS segment, $91.4 million in asset impairments (including $64.6 million for PCS-Massachusetts and $17.2 million for PCS-China), and a $30.0 million WuXi termination fee. The filing also notes lower PCS sales from reduced demand and pricing pressure.
How did the two business segments perform?
RMS net sales rose 1.1% to $667.0 million, with operating income of $184.5 million. PCS net sales fell 8.8% to $466.4 million, and PCS recorded an operating loss of $379.7 million, mainly due to the goodwill and asset impairments.
How is the company managing its capital and shareholder returns?
The board authorized a $500.0 million repurchase program in July 2010, increased to $750.0 million in October 2010. The $300.0 million accelerated stock repurchase settled on February 11, 2011, and $397.1 million remained under the authorization, with the company intending to complete the initial $500.0 million in 2011. The company has not paid cash dividends and does not intend to in the foreseeable future.
What restructuring and strategic actions did management announce?
In December 2010, management announced four initiatives covering operating margin, free cash flow, disciplined growth investment, and shareholder returns. It is pursuing strategic alternatives for the U.S. Phase I clinic in Tacoma, Washington, now presented as discontinued operations, and for the China preclinical facility. In November 2010 it also announced headcount reductions of about 4% and other cost-savings actions.
What are the main risks to the outlook noted in the filing?
The filing cites possible declines in preclinical outsourcing, reductions in pharmaceutical and biotechnology R&D budgets, and reduced or delayed government NIH funding. Customer contracts are generally terminable on little or no notice, many contracts are fixed price, and the company has $700.9 million of debt. It also cites the potential effect of U.S. tax law changes and the health care reform legislation enacted in March 2010.
06—Continue